Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways.

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy ...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) ...

The skin, as the body’s largest organ, serves as a dynamic interface between internal systems and environmental influences.

New research suggests drinking black coffee may protect your liver. Experts break down the findings, caveats, and how to get ...

The peer-reviewed publication this week in Nature Publishing Cell Death & Disease(1) provides compelling support for the hypothesis that iron dysregulation is not merely a bystander, but a potential ...

Prestigious European Society for Medical Oncology Conference “trials-in-progress” sessionPivotal OVATION 3 trial of its DNA-mediated ...

Link, which develops a lot of broadband routers, WiFi extenders and smart home devices for network operators and consumers, ...

In response to the increasing demand for flexible, high-performance signal sources, SIGLENT introduces the SDG3000X Series ...

STOCKHOLM, SE / ACCESS Newswire / October 14, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the n ...